Current research around synucleinopathies and tauopathies focus more on imaging techniques or the different forms of tau protein and amyloid-beta, cytokines, or neurofilament light chain in the serum or CSF (Saeed et al. 2017; Hall et al. 2018; Starhof et al. 2018; Santaella et al. 2020; Chouliaras et al. 2022; Tokutake et al. 2022), so there are a lack of publications investigating other biomarkers. This evidence concerns the gene MAPT and tauopathy.